# A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

> **NCT01423539** · PHASE2 · WITHDRAWN · sponsor: **Genentech, Inc.**

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** bendamustine
- **DRUG:** navitoclax
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT01423539
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-10
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The NAVIGATE study has been terminated due to non-safety related reasons.
- **Last updated:** 2016-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423539, "A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT01423539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*